Document:

EXHIBIT 10.05

 

 

EMPLOYMENT AGREEMENT

 

THIS EMPLOYMENT AGREEMENT
(the "Agreement") is made and entered into as of June 1, 2016, by and between Nexeon MedSystems, Inc.,
a corporation organized under the laws of Nevada (the “Company”) and Melanie McWade ("Executive").

 

R E C I T A L S

 

The Company has special
expertise in its business that has enabled it to provide unique career opportunities for its employees.

 

The Company’s growth
depends, to a significant degree, on its possession of more and better information than that available to its competitors concerning
a number of matters, including but not limited to strategic, marketing, technical, management and other information not generally
known to others in the Company’s industry. This unique and special expertise in pooling this information has enabled the
Company to conduct its business successfully and thus provide potential employment opportunities for its employees.

 

The parties acknowledge
that Executive has her own valuable knowledge and training in certain of the areas in which the Company conducts its business but
that her knowledge will be enhanced by this employment.

 

Executive recognizes that
unless the Company imparts to her its special expertise, she would be less effective and of less benefit to the Company. Executive
further acknowledges that without the additional knowledge to be imparted to her by the Company, she will be less valuable than
would otherwise be the case in its business.

 

Executive understands and
acknowledges that a restriction on disclosure of confidential information is essential to the continued growth and stability of
the Company's business and to the continuing viability of its business in the event the Executive's employment is terminated as
expressly permitted under the terms and limitations of this Agreement.

 

The Executive desires employment
as an employee of the Company under the terms and conditions of this Agreement and further desires to be given access to the Company’s
proprietary information.

 

The Company desires to
employ Executive under the terms and conditions of this Agreement.

 

NOW, THEREFORE, in consideration
of the mutual covenants and agreements set forth in this Agreement, the parties agree as follows:

 

1.     Employment. Subject to the
terms and conditions set forth in this Agreement, the Company employs Executive, and Executive hereby accepts such employment by
the Company.

 

2.     Duties of Executive.

 

(a)     Executive shall serve in the capacity
of Vice President of Emerging Therapies, and shall be subject to supervision by the CEO of the Company. In such capacity, Executive
shall have all necessary powers to discharge her responsibilities. Executive shall have all powers granted by the Bylaws of the
Company to a President, as applicable, and Executive shall report to the Chairman of the Company.

 

    	1

    	 

    

 

(b)     During the term of this Agreement,
and thereafter so long as Executive is employed by the Company, Executive shall devote her full business time and effort to the
performance of her duties and responsibilities as an officer of the Company. Notwithstanding the foregoing, Executive may spend
reasonable amounts of time on personal civic and charitable activities that do not interfere with the performance of her duties
and responsibilities to the Company. In addition, Executive may, subject to prior approval by the Board of Directors of the Company,
spend reasonable amounts of time serving on boards of directors for other companies or engage in other business activities, provided
that such activities do not, in the sound discretion of the Board of Directors of the Company, constitute or create a conflict
of interest or adversely affect the Company.

 

(c)     Executive shall observe and comply
with the written rules and regulations of the Company respecting its business and shall carry out and perform the directives and
policies of the Company as they may from time to time be stated to Executive in writing by the Chief Executive Officer or the Chairman
of the Board of Directors.

 

(d)     Executive shall maintain accurate
business records as may from time to time be required by the Company. Such records may be examined by the Company, at all reasonable
times after written request is delivered to Executive. Any such document shall be delivered to the Company promptly upon request.

 

(e)     Executive agrees not to solicit
or receive any income or other compensation from any third party in connection with her employment with the Company. Executive
agrees, upon written request by the Chief Executive Officer, to render an accounting of all transactions relating to her business
endeavors during the term of this employment hereunder.

 

(f)     Executive’s principal place
of work shall be located at 922 Benton Ave Nashville, TN 37204

 

(g)     Executive agrees to travel, at Company
expense, as required to perform the duties of the position. The Parties anticipate that a minimum of zero (0), maximum of fifteen
(15), and average of five (5) days each month of domestic and/or international travel will be required to perform the duties of
this position.

 

3.     Term. The term of this Agreement
(the "Term") shall commence effective as of June 1st, 2016 (the "Effective Date") and continue until
the fourth anniversary of the Effective Date, unless Executive’s employment is earlier terminated in accordance with Section
10 of this Agreement; provided, however, that, on the fourth and subsequent anniversary dates of this Agreement or any extension,
this Agreement will automatically be extended for an additional year unless, not later than ninety (90) calendar days prior to
such anniversary date, the Company shall have given written notice to the Executive that it does not wish to extend the Term. Upon
expiration of the term of this Agreement, Executive shall remain an “at will” employee of the Company but shall still
be subject to and bound by the terms of this Agreement.

 

4.     Salary and Initial Accrual.

 

(a)     Commencing on the
Effective Date, the Company will pay Executive a minimum base annual salary during the term of this Agreement for her services
as an officer of eighty thousand dollars $80,000.00, which except as described in Section 4(b), shall be payable in accordance
with the Company’s standard payroll practice, but not less than monthly. Such base salary shall not include any benefits
made available to Executive or any contributions or payments made on her behalf pursuant to any employee benefit plan or program
of the Company, including any health, disability or life insurance plan or program, 401-K plan, cash bonus plan, stock incentive
plan, retirement plan or similar plan or program of any nature. The Company shall review Executive's salary on a semi-annual basis
(January and July), and shall increase the annual salary of Executive from time to time as may be warranted in accordance with
the Company’s compensation policies.

 

    	2

    	 

    

 

5.     Bonus Compensation. The Company
shall pay Executive an annual bonus in accordance with Company policy established by the Board from time to time, as described
in Exhibit "A" to this Agreement.

 

6.     Stock Options:

 

(a)     Initial Grant: The Company shall grant Executive a total of two hundred and fifty thousand (250,000) non-transferable stock options
to purchase shares of the Company Common Stock. These options will vest quarterly over a period of three years.

 

7.     Other Employee Benefits.

 

(a)     During the term of this Agreement, the Company shall provide Executive with all benefits made available from time to time by the
Company to its employees and/or officers generally and to employees who hold positions similar to that of Executive (including
benefits granted to other officers of the Company), such benefits to be in accordance with the Company’s policies, except
that if Executive’s employment with the Company is terminated, Executive’s cash severance payments shall be in accordance
with Section 10 of this Agreement, in lieu of cash severance payments provided by the policies of the Company.

 

(b)     Executive shall be paid for Kentucky statutory holidays, and receive twenty (20) working days (“four weeks”)
paid vacation per annum.

 

9.     Reimbursement of Expenses.
The Company shall reimburse Executive for all expenses actually and reasonably incurred by him in the business interests of the
Company. Such reimbursement shall be made promptly to Executive upon appropriate documentation of such expenditures in accordance
with the Company’s written policies.

 

10.    Early Termination; Change in
Control. It is the desire and expectation of each party that the employer-employee relationship shall continue for the full
term specified herein and be a pleasant and rewarding experience for the parties hereto. The Company shall, however, be entitled
to terminate Executive's employment at any time before or after the Effective Date with or without Cause (as defined in this Section
10). Termination shall require approval by majority vote of the Board of Directors of the Company.

 

(a)     Termination for Cause. The Company may terminate Executive’s employment immediately at any time for Cause. For purposes
of this Agreement, “Cause” is defined as: (i) conviction of a felony that constitutes gross negligence, recklessness
or willful misconduct on the part of Executive with respect to Executive’s obligations or otherwise relating to the business
of Company, or for fraud, misappropriation or embezzlement, or any felony or crime of moral turpitude; or (ii) Executive’s
material breach of this Agreement or any other written agreement between Company and Executive. In the event Executive’s
employment is terminated for cause, Executive shall be entitled to all accrued salary including vested Stock and Stock Options,
up through the date of termination but shall not be entitled to additional severance payments.

 

    	3

    	 

    

 

(b)     Termination without Cause, or Change in Control Occurs. The Company may terminate Executive’s employment under this
Agreement without Cause at any time on thirty (30) days advance written notice to Executive. If Executive's employment is terminated
without Cause, or a Change in Control (as defined in this Section 10) occurs, the Company shall pay Executive severance compensation
pursuant to the following formulas:

 

(i)     In the event
of a termination without Cause, or a Change in Control occurs, occurring prior to the first, second, or third year anniversary
of this Agreement, Executive shall receive a lump sum severance amount equal to 3/12th (i.e 25%), 4/12th
or 5/12th respectively of the sum of (A) the highest annual salary of Executive in effect at any time during the Term
or the salary of Executive in effect immediately prior to the termination without Cause or a Change in Control, whichever is the
larger amount, plus (B) the amount of the bonus or incentive compensation targeted for payment to the Executive for the fiscal
year during which the termination without Cause or the Change in Control occurs.

 

(ii)     In the event of a termination without
Cause, or a Change in Control occurs, occurring at any time after the third-year anniversary of this Agreement, Executive will
receive a lump sum severance amount equal to 6/12th of the sum of the amounts referred to in Section 10(b)(i)(A) and
(B).

 

A “Change in
Control” of the Company shall have occurred if at any time during the term of this Agreement any of the following events
shall occur:

 

(i)     any consolidation,
merger or other reorganization of the Company in which the Company is merged, consolidated or reorganized into or with another
corporation or other legal person or pursuant to which shares of the Company’s stock are converted into cash, securities
or other property, other than a merger of the Company in which the holders of the Company’s common stock immediately prior
to the merger own more than 50.1% of the common stock of the surviving corporation or its ultimate parent immediately after the
merger;

 

(ii)     any sale,
lease, exchange or other transfer (in one transaction or a series of related transactions) of all or substantially all of the assets
of the Company and as a result of such transaction the holders of the Company’s common stock immediately prior thereto own
more than 50.1% of the common stock of such transferee or its ultimate parent immediately after such transaction;

 

(iii)     any liquidation
or dissolution of the Company or any approval by the stockholders of the Company of any plan or proposal for the liquidation or
dissolution of the Company;

 

(iv)     any person
(including any “person” as such term is used in Section l3(d)(3) or Section l4(d)(2) of the Exchange Act), has become
an “Acquiring Person.” An “Acquiring Person” shall mean any person that, together with all Affiliates and
Associates (as such terms are defined below) of such person, is the beneficial owner of 25% or more of the outstanding Common Stock.
The term “Acquiring Person” shall not include the Company, any subsidiary of the Company, any employee benefit plan
of the Company or subsidiary of the Company, or any person holding Common Stock for or pursuant to the terms of any such plan.
For the purposes of this Agreement, a person who becomes an Acquiring Person by acquiring beneficial ownership of 25% or more of
the Common Stock at any time after the date of this Agreement shall continue to be an Acquiring Person whether or not such person
continues to be the beneficial owner of 25% or more of the outstanding Common Stock. “Affiliate” and “Associate”
shall have the respective meanings ascribed to such terms in Rule 12b-2 of the General Rules and Regulations under the Securities
Exchange Act of 1934, as amended (the “Exchange Act”) in effect on the date of this Agreement;

 

    	4

    	 

    

 

(v)     if at any time,
the Continuing Directors then serving on the Board cease for any reason to constitute at least a majority thereof. A “Continuing
Director” shall mean a Director of the Company who (aa) is not an Acquiring Person, an Affiliate or Associate, a representative
of an Acquiring Person or nominated for election by an Acquiring Person, and (bb) was either a member of the Board of Directors
of the Company on the date of this Agreement or subsequently became a Director of the Company and whose initial election or initial
nomination for election by the Company’s stockholders was approved by at least two-thirds of the Continuing Directors then
on the Board of Directors of the Company;

 

(vi)     any occurrence
that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A or any successor rule or regulation
promulgated under the Exchange Act; or

 

(vii)     such other
events that cause a change in control of the Company;

 

provided, however, that a
Change in Control of the Company shall not be deemed to have occurred as the result of any action having one or more of the foregoing
effects if such transaction is proposed by, and includes a significant equity participation (i.e., an aggregate of at least 25%
of the then outstanding common equity securities of the Company immediately after such transaction which are entitled to vote to
elect any class of Directors) of, the executive officers of the Company as constituted immediately prior to the occurrence of such
transaction or any Company employee stock ownership plan or pension plan.

 

(c)     Termination Upon Death or Disability. Executive’s employment shall be terminated by the death of the Executive. In
the event of the Disability (as hereinafter defined) of the Executive during her employment, the Company shall have the right to
terminate the employment of Executive upon giving thirty (30) days advance written notice to that effect to the Executive, provided
that the Executive shall not have returned to active service with the Company prior to the end of such thirty (30) day notice period.
For purposes of this Agreement, the term “Disability” means any physical or mental disability or incapacity
that can be expected to result in death within one year or that has rendered the Executive incapable of performing the essential
functions required of the Executive in accordance with the obligations under Section 2 hereof for a period of one hundred and eighty
(180) consecutive days or for shorter periods aggregating to two hundred and seventy (270) days during any consecutive three hundred
and sixty five (365) day period. If Executive is terminated as a result of death, Executive’s estate shall receive a severance
equal to 1/12th of the sum of the amounts referred to in Section 10(b)(i)(A) and (B), less federal and state income
and employment taxes. In the event of termination due to Disability, Executive will receive a severance equal to 6/12th
of the sum of the amounts referred to in Section 10(b)(i)(A) and (B), less federal and state income and employment taxes.

 

(d)     Termination for Good Reason. The Executive, upon ninety (90) days prior written notice given to the Company, shall have
the right at any time to terminate the Executive’s employment with the Company for Good Reason. “Good Reason”
shall mean (i) the occurrence, without the Executive’s express written consent, of a material reduction in Executive’s
duties and responsibilities, or a ten percent (10%) reduction in the level of the Executive’s compensation, unless such reduction
applies to all similarly situated employees; (ii) a demand, without the Executive’s express written consent, that the Executive
relocate to an office of the Company more than twenty-five (25) miles from the office in which the Executive was previously employed;
or (iii) the Company’s uncured breach of a material term of this Agreement.

 

    	5

    	 

    

 

In the event the Executive’s
employment is terminated for Good Reason, Executive will receive a severance payment equal to 3/12th of the sum of the
amounts referred to in Section 10(b)(i)(A) and (B), less federal and state income and employment taxes.

 

(e)     Notice and Opportunity to Cure. Notwithstanding the foregoing, it shall be a condition precedent to the Company’s
right to terminate the Executive’s employment for Cause and the Executive’s right to terminate employment for Good
Reason that (i) the Party seeking the termination shall first have given the other Party written notice stating with specificity
the reason for the termination (“Termination Breach”) and (ii) if such Termination Breach is susceptible to
cure or remedy, a period of thirty (30) days from and after the giving of such notice shall have elapsed without the breaching
Party having substantially cured or remedied such Termination Breach, unless such breach cannot be cured or remedied within thirty
(30) days, in which case the period for remedy or cure shall be extended for a reasonable time not to exceed an additional thirty
(30) days provided the breaching Party has made and continues to make a diligent effort to effect such remedy or cure.

 

(f)     Voluntary Resignation by Executive. Executive may voluntarily resign Executive’s position with Company at any time
on thirty (30) days’ advance written notice to the Company’s Board. In the event Executive’s resignation is without
Good Reason, Executive shall be entitled to receive only the Annual Base Salary then in effect, prorated to the date of termination
and all Stock and Stock Options vested as of the date of termination. All other Company obligations to Executive pursuant to this
Agreement will become automatically terminated and completely extinguished.

 

(g)     Conditions to Receive Severance. Executive agrees to execute a full general release satisfactory to the Company, releasing
all claims, known or unknown that Executive may have against Company arising out of or in any way related to Executive’s
employment or termination of employment with Company prior to receipt of the severance payment. Company shall provide Executive
with a signed, full general release on or prior to the termination date. If Company fails to provide Executive with a signed, full
general release within seven (7) days of the termination date, then Company shall waive this requirement. Any severance due shall
be paid in full within seven (7) days of the termination date, and execution or waiver of the full general release as applicable.

 

11.    Non-Solicitation Agreement.

 

(a)     Executive agrees that for a period
of one (1) year after the termination of this Agreement, Executive shall not recruit, attempt to recruit or directly or indirectly
participate in the recruitment of, any Company employee; provided, however, any general public recruitment responded to by Company
employees will not breach this offer.

 

(b)     Executive agrees that during the
term of this Agreement and for a period of up to one (1) year after the termination of her employment, Executive will not, either
directly or indirectly solicit, separately or in association with others, attempt to solicit, canvass or interfere with any then
current customer of the Company with whom Executive had a significant relationship while working for the Company in a manner that
directly competes with the Company. If Executive is terminated prior to the first anniversary of this Agreement, then the duration
of this obligation will be reduced to equal the number of days that Executive was employed by Company.

 

    	6

    	 

    

 

12.    Confidentiality. Executive
acknowledges that she will learn Confidential Information (as defined herein) relating to the business conducted and to be conducted
by the Company. The Company promises to provide all needed Confidential Information to the Executive. Executive agrees that she
will not during the term of employment with the Company or for a period of three (3) years after the termination of such employment,
without regard to the party terminating such employment, except in the normal and proper course of her duties hereunder, disclose
or use or authorize any third party to disclose or use any such Confidential Information, without prior written approval of the
Company. As used in this Section 12, “Confidential Information” includes all records, designs, business plans, financial
statements, customer lists, manuals, memoranda, lists, research and development plans, Intellectual Property and other property
delivered to or compiled by the Executive by or on behalf of the Company or its providers, clients or customers that pertain to
the business of the Company. Confidential Information shall not, however, include information that (i) is publicly known or becomes
publicly known through no fault of Executive, or (ii) is generally or readily obtainable by the public, or (iii) constitutes general
skills, knowledge and experience acquired by Executive before and/or during her employment with the Company and the Company.

 

Executive agrees that all
documents that include any Confidential Information, in her possession now or at any time during the term of her employment, are
and shall be the property of Company and that all copies thereof shall be surrendered to the Company upon termination of her employment.

 

13.    Inventions; Developments.
The Executive is hereby retained in a capacity such that the Executive’s responsibilities may include the making of technical
and managerial contributions of value to the Company. The Executive hereby assigns to the Company all rights, title and interest
in such contributions and inventions made or conceived by the Executive alone or jointly with others during the Term. This assignment
shall include (a) the right to file and prosecute patent applications on such inventions in any and all countries, (b) the patent
applications filed and patents issuing thereon, and (c) the right to obtain copyright, trademark or trade name protection for any
such work product. The Executive shall promptly and fully disclose all such contributions and inventions to the Company and assist
the Company in obtaining and protecting the rights therein (including patents thereon), in any and all countries; provided, however,
that said contributions and inventions will be the property of the Company, whether or not patented or registered for copyright,
trademark or trade name protection, as the case may be. Inventions conceived by the Executive, which are not related to the business
of the Company, will remain the property of the Executive, and notwithstanding the foregoing, the Company shall not have any right,
title or interest in any work product or copyrightable work developed outside of work hours and without the use of Company resources
that does not relate to the Company’s business and does not result from any work performed by the Executive for the Company.

 

14.    Exit Interview. To insure
a clear understanding of this Agreement, including but not limited to the protection of the Company’s business interests,
Executive agrees, at no additional expense to the Company, to engage in an exit interview with the Company prior to Executive's
departure from the Company at a time and place designated by the Company. In the event that the exit interview takes place in a
location more than twenty-five (25) miles from the Executive’s primary residence, the Company agrees to reimburse Executive
for reasonable expenses associated with her travel to and from said exit interview.

 

15.    Right of Setoff. The Company
shall be entitled, at its option and not in lieu of any other remedies to which they may be entitled, to set off any amounts due
Executive or any Affiliate of Executive against any amount due and payable by Executive or any Affiliate of Executive to the Company
("Set-Offs") pursuant to this Agreement or otherwise, provided that the Set-Offs are set forth in detail in writing with
supporting evidence to substantiate each Set-Off.

 

    	7

    	 

    

 

16.    Notice Provision. Any notice,
demand or request required or permitted to be given or made under this Agreement shall be in writing and shall be deemed given
or made when delivered in person, when sent by United States registered or certified mail, or when received by courier (e.g. FedEx),
at the address specified below:

 

	 	If to the Company:	Nexeon MedSystems,
will@nexeonmedsystems.com
	 	 	 
	 	If to Executive:	Melanie McWade,
PhD
	 	 	922 Benton Avenue, Nashville, TN
37204

 

Any party to this Agreement
may change its addresses for notice in the manner provided above.

 

17.    Headings Non-binding. All
section titles and captions in this Agreement are for convenience only, shall not be deemed part of this Agreement, and in no way
shall define, limit, extend or describe the scope or intent of any provisions hereof.

 

18.    Words to have Contextual Meaning.
Whenever the context may require, any pronoun used in this Agreement shall include the corresponding masculine, feminine or neuter
forms, and the singular form of nouns, pronouns and verbs shall include the plural and vice versa. Additionally, the words “and”
and “or” shall be given its contextual meaning and not be interpreted blindly as being solely conjunctive or disjunctive,
as the case may be.

 

19.    Execution of Agreement. The
parties shall execute all documents, provide all information and take or refrain from taking all actions as may be reasonably necessary
or appropriate to achieve the purposes of this Agreement.

 

20.    Partial Assignment Clause.
This Agreement shall be binding upon and inure to the benefit of the parties hereto, its representatives and permitted successors
and assigns. Executive's duties hereunder are personal services and are not assignable. Except for the provisions of Sections 11,
12 and 13 of this Agreement, which are intended to benefit the Company and the Company's Affiliates as third party beneficiaries,
or as otherwise expressly provided in this Agreement, nothing in this Agreement, express or implied, is intended to confer upon
any person other than the parties to this Agreement, its respective representatives and permitted successors and assigns, any rights,
remedies or obligations under or by reason of this Agreement.

 

21.    Limitation of Benefits Clause.
None of the provisions of this Agreement shall be for the benefit of or enforceable by any creditors of the parties, except as
otherwise expressly provided herein.

 

22.    Non-waiver Provision. No
failure by any party to insist upon the strict performance of any covenant, duty, agreement or condition of this Agreement or to
exercise any right or remedy consequent upon a breach thereof shall constitute waiver of any such breach or any other covenant,
duty, agreement or condition.

 

23.    Multiple Originals. This
Agreement may be executed in counterparts, all of which together shall constitute one agreement binding on all the parties hereto,
notwithstanding that all such parties are not signatories to the original or the same counterpart.

 

24.    Choice of Laws. This agreement
shall be construed in accordance with and governed by the laws of the State of Texas, without regard to the principles of conflicts
of law.

 

25.    Attorneys’ Fees. Each
side will bear its own attorneys’ fees in any dispute unless a statutory or contractual section at issue, if any, authorizes
the award of attorneys’ fees to the prevailing party.

 

    	8

    	 

    

 

26.    Severability and Reformation.
If any provision of this Agreement is declared or found to be illegal, unenforceable, or void, in whole or in part, then the parties
shall be relieved of all obligations arising under such provision, but only to the extent that it is illegal, unenforceable or
void, it being the intent and agreement of the parties that this Agreement shall be deemed amended by modifying such provision
to the extent necessary to make it legal and enforceable while preserving its intent or, if that is not possible, by substituting
therefor another provision that is legal and enforceable and achieves the same objectives.

 

27.    Written Amendments Provision.
No supplement, modification or amendment of this agreement or waiver of any provision of this Agreement shall be binding unless
executed in writing by all parties to this Agreement. No waiver of any of the provisions of this Agreement shall be deemed or shall
constitute a waiver of any other provision of this Agreement (regardless of whether similar), nor shall any such waiver constitute
a continuing wavier unless otherwise expressly provided.

 

28.    Actions to Enforce Non-Solicitation,
Confidentiality or Inventions. Executive acknowledges and agrees that the Company would be irreparably harmed by any violation
of Executive's obligations under Sections 11, 12 and 13 hereof and that, in addition to all other rights or remedies available
at law or in equity, the Company will be entitled to injunctive and other equitable relief to prevent or enjoin any such violation.
Additionally, both parties agree that either party may seek to have its rights under Sections 11, 12 or 13 of this agreement enforced
by legal or equitable action in a Court of Competent jurisdiction. The provisions of Sections 11, 12 and 13 hereof will survive
any termination of this Agreement, in accordance with its terms.

 

29.    Written Consent for Assignment.
No party may assign this Agreement or any rights or benefits thereunder without the written consent of the other parties to this
Agreement.

 

30.    Choice of Forum. Any action
initiated pursuant to Section 28 must proceed in a Texas District Court in Dallas or Collin County, Texas. If such an action cannot
proceed in District Court due to jurisdictional limitations, then it shall proceed in any State or County court of competent jurisdiction
in Dallas or Collin County, Texas.

 

EXECUTED as of the date
first above written.

 

	 	Nexeon MedSystems, Inc.
	 	 
	 	 
	 	By:	/s/ Will Rosellini
	 	 	Will Rosellini
Chief Executive Officer

 

	 	 	 	 
	 	 	 	 
			 	/s/ Melanie McWade
		 	Dr. Melanie McWade , Individually
		 	 

 

 

    	9

    	 

    

 

EXHIBIT A

 

 

Annual Bonus

 

In addition to the base annual salary described
in Section 4 of this Agreement, Executive shall be eligible for an annual performance-based bonus. Executive’s standard bonus
percentage is twenty (20%) of her annual base salary, to be earned by satisfactorily meeting criteria established by the CEO and
approved by the Company Compensation Committee prior to March 1, each year. Executive will receive the full twenty percent (20%)
bonus amount if such criteria are satisfactorily met. In the event that Executive’s performance exceeds this standard, Executive
may be considered for a bonus in an amount larger than the standard bonus percentage stated above. In the event that Executive’s
performance falls short of this standard, Executive may receive less than the full bonus percentage.

 

 

A minimum of seventy percent (70%) of the Annual
Bonus shall be paid in cash, and the balance shall be paid in unrestricted common stock, or such other mutually agreeable consideration.
During the Term of this Agreement, the yearly annual bonus shall be paid within sixty (60) days of the calendar year end.EXHIBIT 10.06

 

 

Nexeon
Director Services Agreement

 

 

Director
Services Agreement made as of May 1, 2016 between Nexeon MedSystems Inc, a Nevada Corporation, (hereinafter the “Company”)
and Dr. Mark Bates MD (hereinafter “Director”).

 

Introduction.
The Company is a Nevada corporation with Bylaws that provide for a Board of Directors to be elected by the holders of a majority
of the issued and outstanding shares of common stock in the Company (“Shares”), whereby said members of the
Board of Directors are responsible for overseeing the Company’s management, their duties and compensation, and elect its
officers. The Company wishes the Director to act as one of its Directors and Director hereby agrees to do so under the terms and
conditions of this Agreement.

 

1.     Services.
Director will act as Director of the Company, and as such, will be available on an on call as needed basis subject to reasonable
notice, attend and participate in periodic board meetings (either in person or by telephonic connection), will advise the Company
and its management with respect to its business, and will serve on Board Committees as appointed by the Board of Directors, assuming
the Director agrees that he/she is qualified to serve on such a committee.

 

2.     Compensation.
As Compensation for acting as Director of the Company, the Company will provide Director with the following compensation:

 

2.1    Director’s
Fees. Starting effective with the date on which the Board of Directors passes a resolution authorizing the Company to pay
its Directors an annual Directors Fee, payable in arrears in quarterly installments at the end of each calendar quarter during
which a Director has served as a Director for the Company.

 

2.2    Director’s
Options. At the end of each monthly period that Director serves as a Director of the Company, the Company will grant to Director
a Nonqualified Stock Option (each “an Option”) to purchase Seven Thousand (7,000) shares of the Company’s restricted
common stock, at a price equal to One United States Dollar ($1.00) per share (the Strike Price) of the Company’s pursuant
to the terms and conditions of the Company’s Omnibus Incentive Plan. The term of each Option shall be for a period of four
(4) years from the date of issue of each Option.

 

(a)    Cashless
Procedure for Exercise of an Option. Director may exercise some or all of any Option using the following “Cashless”
procedure. At the time of any such exercise, Director may request the Company to apply, as an offset to the purchase price (the
“Offset”) an amount equal to (a) a number of Shares designated by Director (the “Designated Share Number”)
multiplied by the sum equal to a twenty five percent (25%) discount from the closing price per Share represented by the last trade
of the Company’s common shares on a recognized securities exchange in which a minimum of ten thousand (10,000) Shares shall
have been traded on the day the Director exercises the Option, provided that the Director shall not have made any such day. In
such event the number of shares to be issued to Director will be reduced by the Designated Share Number.

 

    	1

    	 

    

 

2.3     Expenses.
The Company will reimburse Director for all reasonable out of pocket expenses incurred by Director in acting as Director, subject
to Director providing reasonable documentation and subject to the Company’s policies regarding such expenses, provided further
that it is anticipated that such expenses shall primarily consist of travel expenses to Board Meetings, or such other expenses
discussed and approved by the Company’s CEO and/or Board of Directors.

 

2.4    Consulting
Services. In addition to being a Director of the Company said Director shall also provide Consulting Services to the Company
as its Chief Innovation Officer. Upon the execution hereof Director shall be paid a monthly consulting fee in the amount of Three
Thousand Five Hundred Dollars ($3,500). 

 

3.     Disclosure
of Information, Assignment of Intellectual Property, and Restrictive Covenant:

 

3.1    Acknowledgment.
Director acknowledges that the Company is in the business of producing and selling advanced batteries; that the Company has developed
an excellent reputation and extensive "know-how" and trade secrets relating to its business and its customers, some
of which Director will learn while associated with the Company; and that, the Company has spent substantial amounts of effort
and money to accumulate this know-how and trade secrets and develop its reputation and its relationship with its clients.

 

3.2    Confidential
Information. Director recognizes and acknowledges that the Company’s Confidential Information includes information or
trade secrets relating to the properties, composition or structure of the Company’s products or proposed products or the
development, formulation or processing thereof or hardware, information technology, and software, or the Company’s business,
including, without limitation, any and all patents, patents-pending, patent applications, copyrights, trademarks, service marks,
patentable processes and/or products in development, or any other intellectual property, all trade secrets and proprietary information
concerning the Company’s business and affairs, product specifications, data, know-how, formula, compositions, processes,
designs, sketches, photographs, graphs, drawings, samples, inventions and ideas, past, current and planned research and development,
customer or supplier lists, current and anticipated customer requirements, price lists, market studies, business plans, computer
software and programs and database technologies, systems, structures and architectures and related processes, formula, compositions,
improvements, devices, know-how, discoveries, concepts, ideas, designs, method, algorithms, names and expertise of the Company’s
employees and consultants, inventions (whether patentable or not), schematics and other technical, business, financial, customer
and product development plans, forecasts, strategies and information, whether or not marked “confidential. Additionally,
Director recognizes that in the course of Director’s duties, Director will have access to similar information of the Company’s
customers, suppliers or other entities which the Company is required by contract or professional business practices to keep confidential,
and which shall also be deemed as Confidential Information, which Director agrees to treat as such. Director will not, during
or after the term of this agreement, in whole or in part, disclose any Confidential Information to any person, firm corporation,
association or other entity for any reason or purpose whatsoever, nor shall Director make use of such information and property
for his own purposes or for the benefit of any other person, firm, corporation, association or any other entity (except for the
Company) under any circumstances during or after the term of this Agreement.

 

    	2

    	 

    

 

3.3    Assignment
of Intellectual Property. Director agrees to assign and hereby assigns to the Company (the “Assignment”) any and
all rights, improvements, and copyrightable or patentable subject matter and other intellectual property relating to the Company
business, which Director conceives or develops, either alone or with others, or which otherwise arise during the term of Director
providing management services to the Company and for a period of six (6) months thereafter (“Assignable Property”).

 

3.4    Additional
Cooperation. Director agrees not to assert any rights against the Company or seek compensation from the Company for the foregoing
assignment or the Company’s use of Assignable Technology. Director will promptly disclose to the Company all knowledge that
Director obtains regarding Assignable Property, and at the request of the Company, and without expense or additional compensation,
Director will provide the Company with whatever assistance, including (i) signing whatever documents as are requested by the Company
to further evidence and perfect the Assignment and obtain for the Company patents, copyright protection, assignment of rights
and protection of trade secrets, or (ii) taking any other action the Company deems appropriate for securing or protecting its
rights in Assignable Property or other intellectual property of the Company.

 

3.5    Company
Property. Director recognizes that all materials that are or which may come into Director's possession during the time Director
acts as a Director to the Company relating to the nature, operation, or activities of the Company remain the Company's property.
Such materials may consist of agreements, invoices, memorandum, books, forms, reference materials, computer programs, trade secrets,
copyrights, trademarks, specifications, designs, programming, promotional material, advertising material, selling material, financial
material, address books, lists, rolodex’s, notes, information pertaining to negotiations, pricing procedures, technical
data and the like. All such materials are the Company's property and Director will not copy or make extracts of any such materials
and will promptly return all such materials to the Company upon demand or, regardless of whether such demand is made, after the
termination of Director’s association with the Company.

 

3.6    Limited
Non-Competition. For a period of eighteen (18) months after Director ceases to be a Director of the Company, Director shall
not become, directly or indirectly, an employee of, or provide consulting services for, or have any ownership interest in, any
other business entity that manufactures or sells “Competitive Products”. As used herein, “Competitive Products”
means: (a) any product which the Company develops or acquires the right to sell from time to time during the term of this Agreement.

 

3.7    Director acknowledges that the foregoing provision’s restrictions and time limitations are reasonable and properly required
for the adequate protection of the business of the Company and that in the event such restriction or limitation is deemed to be
unreasonable by an arbitration panel or a Court, then Director agrees to submit to the reduction of said restriction and limitation
to such as the Court may deem reasonable.

 

    	3

    	 

    

 

3.8    It is the desire and intent of the parties that the provisions of this paragraph shall be enforced to the fullest extent possible
under the laws and public policies applied in each jurisdiction which enforcement is sought. Accordingly, if any particular provision
of this Agreement or portion of this paragraph shall be adjudicated to be invalid or unenforceable, then the subject provision
or paragraph shall be deemed amended or deleted here from, and the provision or paragraph adjudicated to be invalid and unenforceable
shall be deemed revised in accordance with any such jurisdiction. Such deletion or revision, however, applies only with respect
to the operation of this Agreement in the particular jurisdiction in which such adjudication is made.

 

3.9    In the event of a breach of, or threatened breach by Director of the provisions set forth in this section 3, the Company shall
be entitled to (i) an injunction restraining Director from violating these covenants and (ii) payment by Director of the expenses
of obtaining and enforcing such relief. Nothing herein shall be construed as prohibiting the Company from pursuing any other remedies
available to it for such breach or threatened breach including recovery of damages from Director whereby such damages shall be
paid promptly, including the cost of collection thereof.

 

4.1    Indemnification.
The Company (“Indemnifying Party”) agrees to defend, indemnify and hold harmless Director and its representatives,
successors and assigns (“Indemnitee”) for a period during the time Director serves the Company and for a period of
Two (2) year from the date the Director cease being a Director of the Company from, against and in respect of any and all loss,
liability and expense resulting from:

 

(a)    All
liabilities of the Company regardless of every kind and nature, resulting from the Company’s obligation of this Agreement
without limitation, known or unknown, contingent or otherwise; and

 

(b)    Any
and all loss, damage or deficiency resulting from any misrepresentation or breach of warranty or non-fulfillment of any obligation
by the Company under this Agreement or from any misrepresentation in or omission from any certificate or other instrument furnished
or to be furnished to Director pursuant to this Agreement; and

 

4.2    Claims.
If any Indemnitee receives notice of any claim or the commencement of any action or proceeding with respect to which the Indemnifying
Party is obligated to provide indemnification pursuant to Section 5.1, the Indemnitee shall promptly give the Indemnifying Party
notice thereof. Such notice shall be a condition precedent to any liability of the Indemnifying Party under the provisions for
indemnification contained in this Agreement and shall describe the claim in reasonable detail and shall indicate the amount (estimated
if necessary) of the loss that has been or may be sustained by the Indemnitee. The Indemnifying Party shall elect to compromise
or defend, at such Indemnifying Party’s own expense and by such Indemnifying Party’s own counsel. If the Indemnifying
Party elects to compromise or defend such asserted liability, it shall within 30 days (or sooner, if the nature of the asserted
liability so requires) notify the Indemnitee of its intent to do so, and the Indemnitee shall cooperate, at the expense of the
Indemnifying Party, in the compromise of, or defense against, any such asserted liability. Notwithstanding the foregoing, neither
the Indemnifying Party nor the Indemnitee may settle or compromise any claim over the objection of the other; provided, however,
that consent to settlement or compromise shall not be unreasonably withheld. In any event, the Indemnitee and the Indemnifying
Party may each participate, at its own expense, in the defense of such asserted liability. The Indemnitee shall make available
to the Indemnifying Party any books, records or other documents within its control that are necessary or appropriate for such
defense.

 

    	4

    	 

    

 

4.3    Costs.
If any legal action or other proceeding is brought for the enforcement or interpretation of any of the rights or provisions of
this Agreement, or because of an alleged dispute, breach, default or misrepresentation in connection with any of the provisions
of this Agreement, each party shall pay its own attorneys’ fees.

 

5.    Term.
Director’s term of acting as a Director under this Agreement, and the Term of this Agreement, shall be until either (i)
Director resigns as a Director of the Company or (ii) the majority of the members of the Company’s Board of Directors vote
to remove Director as a Director of the Company; (iii) a majority of the shareholders of the Company vote to elect a Board of
Directors consisting of directors other than Director. Upon the termination of this Agreement, §3 & 4 above shall survive.

 

6.    Miscellaneous.
This Agreement is the entire Agreement as to its subject matter and it supersedes all prior discussions and oral agreements. This
Agreement may not be modified orally, but only by a written amendment or agreement signed by both parties. This Agreement shall
be governed by the internal laws of the State of Nevada.

 

In Witness Whereof the parties hereto have
signed or caused to be signed this Agreement as of the date first set forth above.

 

	Nexeon MedSystems Inc	 	Director
	 	 	 	 
	 	 	 	 
	By:	/s/
    William Rosellini	 	/s/
    Mark Bates
	 	William Rosellini, CEO	 	Dr. Mark Bates MD

 

 

 

 

    	6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00259-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00259-of-00352.parquet"}]]